Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab govitecan versus physician's choice chemotherapy in first-line advanced triple-negative breast cancer
2023-504195-14-00Phase 3Authorised
- Sponsor
- Gilead Sciences
- Start
- Aug 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 30
01
Overview
Phase 3, randomised, open-label trial of sacituzumab govitecan in triple-negative breast cancer (TNBC) (2 arms), sponsored by Gilead Sciences. Primary endpoint: Progression-free survival. Planned start Aug 2022; status: authorised.
02
Drugs
sacituzumab govitecan
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2023-504195-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504195-14-00.